Drug Profile
Cinrebafusp alfa - Pieris Pharmaceuticals/Servier
Alternative Names: HER2/41BB bispecific; PRS-343Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Pieris Pharmaceuticals
- Developer Eli Lilly and Company; Pieris Pharmaceuticals; Seagen
- Class Antineoplastics; Immunotherapies; Lipocalins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Gastric cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 14 Dec 2023 Seagen has been acquired by Pfizer